Kotaro Matsumoto

Kotaro Matsumoto

Auto-generated profile, based on publicly available information

Kotaro Matsumoto

Division of Rheumatology, Department of Internal Medicine Keio University School of Medicine Tokyo Japan

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in Vector-Borne and Zoonotic Diseases
Verified
Journal Article
Closed access
AYAdrian Ybañez
Adrian Ybañez
MTMichihito Tagawa
Michihito Tagawa
KMKotaro Matsumoto
Kotaro Matsumoto
TKToshio Kishimoto
Toshio Kishimoto
NYNaoaki Yokoyama
Naoaki Yokoyama
HIHisashi Inokuma
Hisashi Inokuma
Recent molecular analyses of the Anaplasma sp. closely related to Anaplasma phagocytophilum (previously believed to be A. phagocytophilum) in Japan have clarified its distinct phylogenetic position. PCR methods relying on 16S rRNA- and P44/MSP2-based primers designed to detect this species have low sensitivity and specificity. In this study, a highly sensitive and specific nested PCR method using newly designed primers based on heat-shock operon gene (groEL) was developed to detect this species. The method was later used in an epidemiological study testing DNA samples from 85 Ixodid ticks (collected by flagging) and 50 cattle from the same pastureland in Nakaosobetsu, Hokkaido, Japan. Results revealed prevalence rates of 2.4% (2 of 85) in ticks and 2% (1 of 50) in cattle. The present study also reported the first molecular detection of the Anaplasma sp. closely related to A. phagocytophilum in Japan in H. douglasii, and established a new reliable PCR method that detects this Anaplasma sp. closely related to A. phagocytophilum in Japan.

1 September 1996 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
KMK. Matsumoto
K. Matsumoto
ERE. Robb
E. Robb
GWG. Warden
G. Warden
JNJ. Nordlund
J. Nordlund

3 January 2023 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
KMKotaro Matsumoto
Kotaro Matsumoto
KSKatsuya Suzuki
Katsuya Suzuki
HYHiroto Yoshida
Hiroto Yoshida
MMMayu Magi
Mayu Magi
YMYoshihiro Matsumoto
Yoshihiro Matsumoto
YKYuko Kaneko
Yuko Kaneko
Background: Giant cell arteritis (GCA) is a primary large-vessel vasculitis (LVV) of unknown origin. Its management is a challenge due to the late onset of disease symptoms and frequent relapse; therefore, clarifying the pathophysiology of GCA is essential to improving treatment. This study aimed to identify the transition of molecular signatures in immune cells relevant to GCA pathogenesis by analyzing longitudinal transcriptome data in patients. Methods: We analyzed the whole blood transcriptome of treatment-naive patients with GCA, patients with Takayasu arteritis (TAK), age-matched, old healthy controls (HCs), and young HCs. Characteristic genes for GCA were identified, and the longitudinal transition of those genes was analyzed using cell-type identification by estimating relative subsets of RNA transcripts (CIBERSORT). Results: Repeated measures analysis of variance revealed 739 differentially expressed genes among all patients and HCs. Of the 739 genes, 15 were characteristically upregulated and 36 were downregulated in patients with GCA compared to those with TAK and HCs. Pathway enrichment analysis showed that downregulated genes in GCA were associated with B cell activation. CIBERSORT analysis revealed that upregulation of “M0-macrophages” and downregulation of B cells were characteristic of GCA. Upregulation of “M0-macrophages” reflects the activation of monocytes in GCA toward M0-like phenotypes, which persisted under 6 weeks of treatment. Combined treatment with prednisolone and an interleukin-6 receptor antagonist normalized molecular profiles more efficiently than prednisolone monotherapy. Conclusions: Gene signatures of monocyte activation and B cell inactivation were characteristic of GCA and associated with treatment response.

23 February 2005 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
HNHiroshi Nakashima
Hiroshi Nakashima
ATAkira Tasaki
Akira Tasaki
MKMakoto Kubo
Makoto Kubo
HKHideo Kuroki
Hideo Kuroki
KMKotaro Matsumoto
Kotaro Matsumoto
MKMitsuo Katano
Mitsuo Katano

4 September 2020 in Rheumatology
Verified
Journal Article
Closed access
HYHiroki Yamada
Hiroki Yamada
TSTakanori Sasaki
Takanori Sasaki
KMKotaro Matsumoto
Kotaro Matsumoto
KSKatsuya Suzuki
Katsuya Suzuki
MTMasaru Takeshita
Masaru Takeshita
TTTsutomu Takeuchi
Tsutomu Takeuchi
Objectives: PD-1hi CXCR5– T peripheral helper (Tph) cells are newly identified pathogenic CD4 helper T cells in RA. We evaluated the usefulness of Tph cell subsets as biomarkers of RA.Methods: RA patients who visited our rheumatology department between May 2015 and September 2017 and met the 2010 ACR/EULAR classification criteria were included. We compared the correlation of DAS28-ESR between Tph cell subsets and 40 immune cell subsets. We also explored which subsets reflected the chronological changes in the disease activity after treatment.Results: Thirty-four seropositive RA patients, 11 seronegative RA patients and 34 healthy controls were included. Tph cell subsets that correlated with the DAS28-ESR were HLA-DR+ Tph cells (rs = 0.50, P = 0.002), HLA-DR– Tph cells (rs = 0.39, P = 0.03) and Tph1 cells (rs = 0.41, P = 0.02). Among the other 40 immune cell subsets, HLA-DR+ Th1-17 cells (rs = 0.38, P = 0.03), activated B cells (rs = –0.35, P = 0.04), plasma cells (rs = 0.43, P = 0.01) and CD14++ CD16+ monocytes (rs = 0.36, P = 0.04) correlated, but not strongly as HLA-DR+ Tph cells. However, MTX treatment reduced the proportion of HLA-DR+ Tph cells independently of the disease activity. In contrast, HLA-DR– Tph cells accurately reflected the change in the DAS28-ESR during MTX treatment.Conclusion: HLA-DR+ Tph cells were decreased with MTX treatment, independent of the disease activity, while HLA-DR– Tph cells reflected the disease activity accurately during the treatment.

3 August 2019 in Rheumatology
Verified
Journal Article
Closed access
KMKotaro Matsumoto
Kotaro Matsumoto
KSKatsuya Suzuki
Katsuya Suzuki
KYKeiko Yoshimoto
Keiko Yoshimoto
NSNoriyasu Seki
Noriyasu Seki
HTHideto Tsujimoto
Hideto Tsujimoto
TTTsutomu Takeuchi
Tsutomu Takeuchi
Objectives: To elucidate the association between clinical characteristics and immuno-phenotypes in patients with ANCA-associated vasculitis (AAV).Methods: Peripheral blood from 36 patients with active AAV and 18 healthy controls was examined for numbers of circulating T cells, B cells, NK cells, dendritic cells, monocytes and granulocytes using flow cytometry. These immuno-phenotyping data were subjected to cluster analysis and principal components analysis to divide AAV patients into subgroups. Associated organ involvement or therapeutic prognosis were assessed for each subgroup.Results: AAV patients had higher proportions of plasma cells, plasmablasts, activated T cells, CD14++ CD16+ monocytes, eosinophils and neutrophils than healthy controls. Immuno-phenotyping findings were similar between patients with microscopic polyangiitis, granulomatosis with polyangiitis and eosinophilic granulomatosis with polyangiitis. Cluster analysis indicated that AAV patients could be divided into three subgroups according to peripheral immune cell numbers: antibody production-related (n = 9), cytotoxic activity-related (n = 4) and neutrocytosis/lymphocytopenia-related (n = 23). The antibody production-related or cytotoxic activity-related group was associated with CNS involvement, and the neutrocytosis/lymphocytopenia-related group was associated with high incidence of kidney involvement. Incidence of severe infection was markedly higher in the neutrocytosis/lymphocytopenia-related group than the other two groups. Incidence of disease relapse was comparable among the three groups.Conclusion: Patients with active AAV can be divided into three subgroups based on immuno-phenotyping. These results may provide a hint to understanding disease pathophysiology and prognosis, and determining appropriate treatment.